L & S Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.79M | Buy |
30,958
+19,350
| +167% | +$4.16M | 0.81% | 49 |
|
|
2026
Q1 | $2.52M | Sell |
11,608
-23,456
| -67% | -$5.2M | 0.32% | 89 |
|
|
2025
Q4 | $8.01M | Sell |
35,064
-7,793
| -18% | -$1.78M | 0.74% | 30 |
|
|
2025
Q3 | $9.92M | Buy |
42,857
+24,606
| +135% | +$5.01M | 0.95% | 31 |
|
|
2025
Q2 | $3.39M | Sell |
18,251
-35,344
| -66% | -$6.57M | 0.34% | 81 |
|
|
2025
Q1 | $11.2M | Buy |
53,595
+35,048
| +189% | +$6.81M | 1.39% | 14 |
|
|
2024
Q4 | $3.3M | Sell |
18,547
-149
| -0.8% | -$27.4K | 0.36% | 77 |
|
|
2024
Q3 | $3.69M | Sell |
18,696
-1,389
| -7% | -$259K | 0.39% | 73 |
|
|
2024
Q2 | $3.44M | Sell |
20,085
-33
| -0.2% | -$5.47K | 0.39% | 64 |
|
|
2024
Q1 | $3.66M | Sell |
20,118
-85
| -0.4% | -$14.6K | 0.41% | 70 |
|
|
2023
Q4 | $3.13M | Sell |
20,203
-35,023
| -63% | -$5.11M | 0.38% | 71 |
|
|
2023
Q3 | $8.23M | Buy |
55,226
+34,580
| +167% | +$5.08M | 1.18% | 17 |
|
|
2023
Q2 | $2.78M | Sell |
20,646
-30,614
| -60% | -$4.49M | 0.37% | 70 |
|
|
2023
Q1 | $8.17M | Buy |
51,260
+30,416
| +146% | +$4.65M | 1.14% | 19 |
|
|
2022
Q4 | $3.37M | Sell |
20,844
-33,984
| -62% | -$5.21M | 0.62% | 49 |
|
|
2022
Q3 | $7.36M | Sell |
54,828
-16,170
| -23% | -$2.32M | 1.3% | 17 |
|
|
2022
Q2 | $10.9M | Sell |
70,998
-22,781
| -24% | -$3.48M | 1.82% | 8 |
|
|
2022
Q1 | $15.2M | Buy |
93,779
+12,350
| +15% | +$1.79M | 1.8% | 8 |
|
|
2021
Q4 | $11M | Buy |
81,429
+58,934
| +262% | +$6.96M | 1.19% | 14 |
|
|
2021
Q3 | $2.43M | Sell |
22,495
-45,327
| -67% | -$5.18M | 0.26% | 111 |
|
|
2021
Q2 | $7.64M | Buy |
67,822
+20,388
| +43% | +$2.3M | 0.82% | 24 |
|
|
2021
Q1 | $5.13M | Buy |
47,434
+5,839
| +14% | +$625K | 0.58% | 48 |
|
|
2020
Q4 | $4.46M | Buy |
41,595
+6,479
| +18% | +$623K | 0.52% | 62 |
|
|
2020
Q3 | $3.08M | Sell |
35,116
-22,428
| -39% | -$2.11M | 0.42% | 80 |
|
|
2020
Q2 | $5.65M | Buy |
57,544
+35,624
| +163% | +$3.14M | 0.84% | 33 |
|
|
2020
Q1 | $1.67M | Sell |
21,920
-155
| -0.7% | -$13.2K | 0.32% | 76 |
|
|
2019
Q4 | $1.96M | Sell |
22,075
-195
| -0.9% | -$16.2K | 0.25% | 93 |
|
|
2019
Q3 | $1.69M | Sell |
22,270
-1,730
| -7% | -$119K | 0.24% | 114 |
|
|
2019
Q2 | $1.75M | Sell |
24,000
-1,610
| -6% | -$127K | 0.23% | 111 |
|
|
2019
Q1 | $2.06M | Hold |
25,610
| – | – | 0.28% | 85 |
|
|
2018
Q4 | $2.36M | Buy |
25,610
+4,527
| +21% | +$398K | 0.44% | 50 |
|
|
2018
Q3 | $1.99M | Sell |
21,083
-23,467
| -53% | -$2.23M | 0.26% | 90 |
|
|
2018
Q2 | $4.13M | Buy |
44,550
+1,532
| +4% | +$150K | 0.69% | 43 |
|
|
2018
Q1 | $4.07M | Sell |
43,018
-78,586
| -65% | -$8.63M | 0.78% | 37 |
|
|
2017
Q4 | $11.8M | Sell |
121,604
-3,883
| -3% | -$366K | 1.8% | 5 |
|
|
2017
Q3 | $11.2M | Sell |
125,487
-5,328
| -4% | -$406K | 1.87% | 6 |
|
|
2017
Q2 | $9.48M | Buy |
130,815
+12,573
| +11% | +$845K | 1.67% | 6 |
|
|
2017
Q1 | $7.71M | Buy |
118,242
+103,347
| +694% | +$6.5M | 1.47% | 11 |
|
|
2016
Q4 | $933K | Buy |
14,895
+3,289
| +28% | +$201K | 0.21% | 89 |
|
|
2016
Q3 | $732K | Hold |
11,606
| – | – | 0.2% | 77 |
|
|
2016
Q2 | $719K | Buy |
+11,606
| New | +$707K | 0.16% | 71 |
|
|
2016
Q1 | – | Sell |
-57,534
| Closed | -$3.41M | – | 74 |
|
|
2015
Q4 | $3.41M | Buy |
+57,534
| New | +$3.31M | 0.85% | 53 |
|
|
2014
Q4 | – | Sell |
-88,929
| Closed | -$5.14M | – | 76 |
|
|
2014
Q3 | $5.14M | Sell |
88,929
-25,792
| -22% | -$1.43M | 2.52% | 7 |
|
|
2014
Q2 | $6.47M | Buy |
+114,721
| New | +$6.02M | 2.58% | 5 |
|
|
2014
Q1 | – | Sell |
-12,274
| Closed | -$648K | – | 81 |
|
|
2013
Q4 | $648K | Buy |
12,274
+1,576
| +15% | +$77.5K | 0.24% | 54 |
|
|
2013
Q3 | $479K | Sell |
10,698
-939
| -8% | -$41.6K | 0.19% | 52 |
|
|
2013
Q2 | $481K | Buy |
+11,637
| New | +$509K | 0.24% | 38 |
|
Other funds holding ABBV
L & S Advisors's ABBV Position: Q2 2026 in Review
L & S Advisors increased its AbbVie (ABBV) stake by 167% in Q2 2026, buying an estimated $4.16M and bringing the position to 30,958 shares worth $7.79M. The position accounts for 0.81% of the portfolio, ranked #49.
L & S Advisors first reported a position in ABBV in Q2 2013 and has held it in 47 quarters since. The position peaked at $15.2M in Q1 2022. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- L & S Advisors held 30,958 shares of AbbVie worth $7.79M as of Q2 2026.
- L & S Advisors bought 19,350 AbbVie shares in Q2 2026, an estimated $4.16M.
- AbbVie made up 0.81% of L & S Advisors's portfolio in Q2 2026, its #49 holding.
- L & S Advisors first reported a position in AbbVie in Q2 2013 and has held it in 47 quarters since.
- L & S Advisors's AbbVie position peaked at $15.2M in Q1 2022.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on L & S Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.